TSHA Stock: Price, Earnings History and SEC Filings
Taysha Gene Therapies, Inc. (TSHA) last traded at $4.13, down 2.13% on the latest session and down 15.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.13 against an analyst estimate of $-0.11, a miss of 18.2%.
$4.13 -2.13%
1 month-15.20%
52-week high$7.30
52-week low$3.46
Volume1.50M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TSHA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.13 | $-0.11 | -18.18% |
| Mar 2026 | May 6, 2026 | $-0.12 | $-0.10 | -20.00% |
| Dec 2025 | Mar 19, 2026 | $-0.08 | $-0.11 | +27.27% |
| Sep 2025 | Nov 4, 2025 | $-0.09 | $-0.09 | +0.00% |
TSHA beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TSHA
SEC filing data is not available right now. You can search for TSHA on SEC EDGAR.
TSHA news
- Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book ValueOct 30, 2026 · finance.yahoo.com
- Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?Oct 19, 2026 · finance.yahoo.com
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. (TSHA) is a US-listed public company on Nasdaq.